← Back to screener

Neurogene Inc. NGNE

Rank #2220 · Nasdaq · $0.4B market cap
Audited by Deloitte & Touche LLP, no going-concern flag in the latest filing.
Score
28.8
P/E
-5.8
P/B
2.34
ROE
-40.4%
Op. Margin
-8930.3%
Debt Ratio
14%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Weak

P/E -5.8x, P/B 2.34x. Ranks in the top 66% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -40.4%. Ranks in the top 92% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 14%. Ranks in the top 11% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2014––$-0.0B$-0.0B–-19
2015––$-0.0B$-0.1B–-10
2016––$-0.0B$-0.1B–-7
2017––$-0.0B$0.0B–27
2018$0.0B$-0.0B$-0.0B$0.1B-150.611
2019$0.0B$-0.1B$-0.1B$0.1B-204.53
2020–$-0.1B$-0.1B$0.1B–7
2021–$-0.0B$-0.0B$0.1B–14
2022–$-0.1B$-0.1B$0.2B–11
2023–$-0.1B$-0.1B$-0.1B–-12
2024$0.0B$-0.1B$-0.0B$-0.1B–-25
2025$0.0B$-0.1B$-0.1B$0.2B-8930.314

← See the full screener